RAIN
RAIN THERAPEUTICS INC
1 day chart
About RAIN
Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.
Buy US stocks in Australia with $0 brokerage and trade RAIN today!
$116.89M
-
0.00%
9
$5.47
$4.00
$0.00
$17.31
$2.15
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.